share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

CRISPR Therapeutics | 3:首次持股声明-董事 Rommel Christian
美股SEC公告 ·  05/30 16:34

Moomoo AI 已提取核心信息

Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
CRISPR Therapeutics的董事兼10%所有者克里斯蒂安·隆美尔于2024年5月30日向美国证券交易委员会提交了初步的证券实益拥有权声明。表格3申报是1934年《证券交易法》第16(a)条的要求,表明隆美尔不以实益方式拥有公司的任何非衍生或衍生证券。该表格是作为个人而不是联合/团体文件提交的,包括隆美尔的签名和提交日期。
CRISPR Therapeutics的董事兼10%所有者克里斯蒂安·隆美尔于2024年5月30日向美国证券交易委员会提交了初步的证券实益拥有权声明。表格3申报是1934年《证券交易法》第16(a)条的要求,表明隆美尔不以实益方式拥有公司的任何非衍生或衍生证券。该表格是作为个人而不是联合/团体文件提交的,包括隆美尔的签名和提交日期。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息